EU Kills Generics Delay Probe Of AstraZeneca, Nycomed

Law360, New York (March 1, 2012, 2:03 PM EST) -- The European Union’s competition regulator said Thursday it was ending its investigation into pharmaceutical heavies AstraZeneca PLC and Nycomed, after failing to prove the companies made agreements over patents to delay the entry of cheaper drugs into the market.

The European Commission did not provide further details about its decision to drop the probe.

The EC launched surprise raids of AstraZeneca's and Nycomed's facilities and of several other companies in November 2010, after an extensive antitrust investigation into the pharmaceutical sector focusing on the alleged practice...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.